Bionomics is a clinical stage biopharmaceutical company leveraging its proprietary ionX and Multicore platforms to deliver a pipeline of novel drug candidates in central nervous system (CNS) disorders and cancer. Based in Adelaide, Australia, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • Clinical Program Updates

    15 September 2020

    Download PDF

  • Bionomics Presenting at Virtual H.C. Wainwright Global Investment Conference

    09 September 2020

    Download PDF

  • 2019/2020 Preliminary Final Report

    28 August 2020

    Download PDF


Latest Analyst Report